Bambusa Therapeutics, Inc. filed an amended and restated certificate of incorporation and bylaws with the Delaware Secretary of State on November 2, 2026. The filings were made in connection with the completion of the company’s initial public offering (IPO).
The Restated Certificate of Incorporation and the Restated Bylaws are described in the sections titled “Risk Factors” and “Description of Capital Stock” within the company’s Prospectus. This Prospectus was filed with the Securities and Exchange Commission on October 30, 2026, as part of a Registration Statement on Form S-1 (File No. 333-299405).
The Restated Bylaws became effective as of November 2, 2026. The company has filed the full text of both the Restated Certificate of Incorporation and the Restated Bylaws as Exhibits 3.1 and 3.2 to this report.
The registrant is identified as Bambusa Therapeutics, Inc., a Delaware corporation with its principal executive offices located at 22 Boston Wharf Road, Floor 7, Boston, Massachusetts 02210. The company’s common stock trades on The Nasdaq Stock Market LLC under the ticker symbol BBTX.
